Video

Dr. Ruddy on the Importance of Genetic Testing in Breast Cancer

Kathryn Ruddy, MD, discusses how genetic testing could impact treatment of patients with breast cancer.

Kathryn Ruddy, MD, associate professor of Oncology, Mayo Clinic, discusses how genetic testing could impact treatment of patients with breast cancer.

According to Ruddy, it’s important to perform genetic testing for genes like BRCA1 and BRCA2, which have already been determined to play a role in care of women with strong family history of breast cancer or patients diagnosed at a younger age.

Because rates of these mutations are higher in younger women diagnosed with breast cancer, it is best to do genetic testing early as it can impact surgical treatment decisions. It can also be useful in metastatic disease where PARP inhibitors are more effective in patients with BRCA mutations. Ruddy says that even though a patient here may not undergo breast surgery, understanding the mutations can still play a role in selecting systemic therapies.

Related Videos
Ruth M. O’Regan, MD
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Sheldon M. Feldman, MD
Dana Zakalik, MD